Biotransformation of melatonin in human breast cancer cell lines: Role of sulfotransferase 1A1

Journal of Pineal Research

Volumn 39, Issue 3, 2005, Pages 276-282

  Aust, Sylvia ^a   Jaeger, Walter ^b   Klimpfinger, Martin ^c   Mayer, Klaus ^a   Baravalle, Günther ^a   Ekmekcioglu, Cem ^a   Thalhammer, Theresia ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Inst of Pathology and Bacteriology   (Austria)

Author keywords

6 hydroxymelatonin sulfate; Biotransformation; Breast cancer; Melatonin; Sulfotransferase; SULT1A1; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; 6 HYDROXYMELATONIN; 6 HYDROXYMELATONIN SULFATE; ANTIESTROGEN; MELATONIN; MELATONIN DERIVATIVE; MESSENGER RNA; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; BREAST CANCER; CANCER CELL CULTURE; CELL LEVEL; CELL STRAIN; CELL STRAIN MCF 7; CELL STRAIN MDA MB231; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HORMONE DEPENDENCE; HORMONE METABOLISM; HUMAN; HUMAN CELL; MODULATION;

ANTINEOPLASTIC AGENTS, HORMONAL; ARYLSULFOTRANSFERASE; BIOTRANSFORMATION; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOSOL; FEMALE; HUMANS; MELATONIN; RNA, MESSENGER; TAMOXIFEN; TRANSFECTION;

EID: 25144495118     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2005.00246.x     Document Type: Article

References (46)

1. TAN DX, REITER RJ, MANCHESTER LC et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2:181-197.
2. HARDELAND R, COTO-MONTES A, POEGGELER B. Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol Int 2003; 20:921-962.
3. BLASK DE, SAUER LA, DAUCHY RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002; 2:113-132.
4. LEON-BLANCO MM, GUERRERO JM, REITER RJ et al. RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line. Cancer Lett 2004; 216:73-80.
5. NOWFAR S, TEPLITZKY SR, MELANCON K et al. Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin. Breast Cancer Res Treat 2002; 72:33-43.
6. LEON J, ACUNA-CASTROVIEJO D, ESCAMES G et al. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005; 38:1-9.
7. TAN DX, MANCHESTER LC, HARDELAND R et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003; 34:75-78.
8. GIRGERT R, BARTSCH C, HILL SM et al. Tracking the elusive antiestrogenic effect of melatonin: a new methodological approach. Neuroendocrinol Lett 2003; 24:440-444.
9. Cos S, MARTINEZ-CAMPA C, MEDIAVILLA MD et al. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 2005; 38:136-142.
10. DEL RIO B, GARCIA PEDRERO JM, MARTINEZ-CAMPA C et al. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 2004; 279:38294-38302.
11. SANCHEZ-BARCELO EJ, COS S, FERNANDEZ R et al. Melatonin and mammary cancer: a short review. Endocr Relat Cancer 2003; 10:153-159.
12. ANISIMOV VN. The role of pineal gland in breast cancer development. Crit Rev Oncol Hematol 2003; 46:221-234.
13. MA X, IDLE JR, KRAUSZ KW et al. Metabolism of melatonin by human cytochromes P450. Drug Metab Dispos 2005; 33:489-494.
14. MATUSZAK Z, BILSKA MA, RESZKA KJ et al. Interaction of singlet molecular oxygen with melatonin and related indoles. Photochem Photobiol 2003; 78:449-455.
15. DUBOCOVICH ML, RIVERA-BERMUDEZ MA, GERDIN MJ et al. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 2003; 8:1093-1108.
16. YOUNG IM, LEONE RM, FRANCIS P et al. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J Clin Endocrinol Metab 1985; 60:114-119.
17. KVEDER S, MCISAAC WM. The metabolism of melatonin (N-acetyl-5- methoxytryptamine) and 5-methoxytryptamine. J Biol Chem 1961; 236:3214-3220.
18. KOVACS J, BRODNER W, KIRCHLECHNER V et al. Measurement of urinary melatonin: a useful tool for monitoring serum melatonin after its oral administration. J Clin Endocrinol Metab 2000; 85:666-670.
19. COUGHTRIE MW. Sulfation through the looking glass - recent advances in sulfotransferase research for the curious. Pharmacogenomics J 2002; 2:297-308.
20. GLATT H, MEINL W. Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch Pharmacol 2004; 369:55-68.
21. KAUFFMAN FC. Sulfonation in pharmacology and toxicology. Drug Metab Rev 2004; 36:823-843.
22. DOOLEY TP, HUANG Z. Genomic organization and DNA sequences of two human phenol sulfotransferase genes (STP1 and STP2) on the short arm of chromosome 16. Biochem Biophys Res Commun 1996; 228:134-140.
23. HONMA W, KAMIYAMA Y, YOSHINARI K et al. Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. Drug Metab Dispos 2001; 29:274-281.
24. AUST S, OBRIST P, KLIMPFINGER M et al. Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2 and 1C1 in malignant breast tissue. Int J Oncol 2005; 26:1079-1085.
25. HARRIS RM, WOOD DM, BOTTOMLEY L et al. Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. J Clin Endocrinol Metab 2004; 89:1779-1787.
26. ADJEI AA, WEINSHILBOUM RM. Catecholestrogen sulfation: possible role in carcinogenesis. Biochem Biophys Res Commun 2002; 292:402-408.
27. INGLE JN. Adjuvant endocrine therapy in postmenopausal breast cancer. Clin Cancer Res 2003; 9:480-485.
28. PASQUALINI JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 2004; 1654:123-143.
29. CHEN G, YIN S, MAITI S et al. 4-Hydroxytamoxifen sulfation metabolism. J Biochem Mol Toxicol 2002; 16:279-285.
30. NISHIYAMA T, OGURA K, NAKANO H et al. Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 2002; 63:1817-1830.
31. SPINK BC, KATZ BH, HUSSAIN MM et al. SULT1A1 catalyzes 2-methoxyestradiol sulfonation in MCF-7 breast cancer cells. Carcinogenesis 2000; 21:1947-1957.
32. TABRETT CA, COUGHTRIE MW. Phenol sulfotransferase 1A1 activity in human liver: kinetic properties, interindividual variation and re-evaluation of the suitability of 4-nitrophenol as a probe substrate. Biochem Pharmacol 2003; 66:2089-2097.
33. DOOLEY TP, HALDEMAN-CAHILL R, JOINER J, WILBORN TW. Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells. Biochem Biophys Res Commun 2000; 277:236-245.
34. SINGER SS, HAGEDORN JE, SMITH DM et al. The enzymatic basis for the rat liver 6-hydroxymelatonin sulfotransferase activity. J Pineal Res 1995; 18:49-55.
35. BARTSCH C, BARTSCH H. Letter to the editor. J Pineal Res 1996; 20:173.
36. ANGUS WG, LARSEN MC, JEFCOATE CR. Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: role of estrogen receptor status. Carcinogenesis 1999; 20:947-955.
37. ISCAN M, KLAAVUNIEMI T, COBAN T et al. The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res Treat 2001; 70:47-54.
38. OYAMA T, KAGAWA N, KUNUGITA N et al. Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 2004; 9:1967-1976.
39. MAITI S, CHEN G. Tamoxifen induction of aryl sulfotransferase and hydroxysteroid sulfotransferase in male and female rat liver and intestine. Drug Metab Dispos 2003; 31:637-644.
40. AHMED S, OWEN CP, JAMES K et al. Review of estrone sulfatase and its inhibitors - an important new target against hormone dependent breast cancer. Curr Med Chem 2002; 9:263-273.
41. VIJAYALAXMI V, THOMAS CR Jr, REITER RJ et al. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002; 20:2575-2601.
42. REITER RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004; 37:213-214.
43. COS S, BLASK DE, LEMUS-WILSON A et al. Effects of melatonin on the cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells in culture. J Pineal Res 1991; 10:36-42.
44. WILSON ST, BLASK DE, LEMUS-WILSON AM. Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J Clin Endocrinol Metab 1992; 75:669-670.
45. LISSONI P, BARNI S, MEREGALLI S et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995; 71:854-856.
46. CARLINI EJ, RAFTOGIANIS RB, WOOD TC et al. Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 2001; 11:57-68.